GleamWall
中文EN

NXL Nexalin Technology, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1527352 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY76.7%
TTM net income YoY-8.0%
TTM EPS YoY108.1%
Revenue 3-yr CAGR29.2%
Net income 3-yr CAGR—

Margins

Gross margin82.4%
Operating margin-3,386.0%
Net margin-3,380.6%
FCF margin—
EBITDA margin—

Returns

ROE-372.6%
ROA-222.9%
ROIC (approx.)-406.6%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets92.0%
Debt / equity0.00x
Current ratio0.69x
Interest coverage-179.02x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-74.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$301,647$168,721
Cost of revenue$61,373$36,593
Gross profit$240,274$132,128
R&D expense$1.08M$1.19M
SG&A expense$4.40M$4.23M
Operating income-$8.39M-$7.75M
Interest expense-$8,240-$3,193
Pretax income-$8.22M-$7.61M
Net income-$8.22M-$7.61M
EPS (basic)-0.50-0.83
EPS (diluted)-0.50-0.83
Weighted avg. shares (diluted)16.39M9.22M
Banking
Net interest income-$8,240-$3,193
Balance sheet
Cash & equivalents$654,783$574,485
Short-term investments$3.07M$2.91M
Receivables$81,571$13,043
Inventory$131,473$174,578
Current assets$4.30M$3.96M
Intangibles$336,049$260,727
Total assets$4.64M$4.22M
Current liabilities$887,333$546,694
Total liabilities$887,333$546,694
Shareholders' equity$3.75M$3.68M
Shares outstanding639,54413.30M
Cash flow statement
Operating cash flow-$4.96M-$3.94M
Investing cash flow-$131,991-$577,539
Financing cash flow$5.17M$4.52M
Stock-based compensation$3.12M$3.56M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.